DOBUTAMINE HYDROCHLORIDE INJECTION-12.5MG/ML DIN 02225891
Status: Cancelled Post Market
Holder: SANOFI CANADA, INC.
Molecule: DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE)
Health Canada record
| Active ingredient(s) | DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) 12.5 MG |
|---|---|
| Dosage form | Liquid |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C01CA07 DOBUTAMINE |
| Original market date | 21-May-1997 |
| Current status date | 24-Oct-1998 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02462729 | DOBUTAMINE INJECTION USP | HIKMA CANADA LIMITED | Solution | DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) 12.5 MG | Marketed |
| 02242010 | DOBUTAMINE INJECTION USP | SANDOZ CANADA INCORPORATED | Liquid | DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) 12.5 MG | Marketed |
| 02443430 | DOBUTAMINE INJECTION USP | STERIMAX INC | Solution | DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) 12.5 MG | Approved |
| 02229451 | DOBUTAMINE 12.5MG/ML | IVAX PHARMACEUTICALS INCORPORATED | Solution | DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) 12.5 MG | Cancelled Post Market |
| 02228335 | DOBUTAMINE HYDROCHLORIDE INJECTION-12.5MG/ML | NOVOPHARM LIMITED | Liquid | DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) 12.5 MG | Cancelled Post Market |
| 02384671 | DOBUTAMINE INJECTION SDZ | SANDOZ CANADA INCORPORATED | Solution | DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) 12.5 MG | Dormant |
| 02210401 | DOBUTAMINE INJECTION USP | PFIZER CANADA ULC | Solution | DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) 250 MG | Cancelled Post Market |
| 00759538 | DOBUTREX | PHARMACEUTICAL PARTNERS OF CANADA INC | Solution | DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) 12.5 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 6332 | 1996-07-15 | New Drug Submission (NDS) |